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A huge number of compounds are widely distributed in nature and many of these possess
medicinal/biological/pharmacological activity. Curcumin, a polyphenol derived from the
rhizomes (underground stems) of Curcuma longa Linn (a member of the ginger family,
commonly known as turmeric) is a culinary spice and therapeutic used in India for
thousands of years to induce color and flavor in food as well as to treat a wide array
of diseases. The origin of turmeric as spice and folklore medicine is so old that it is
lost in legend. Curcumin has many beneficial pharmacological effects which includes, but
are not limited with, antimicrobial, anti-inflammatory, antioxidant, antiviral, antiangiogenic,
neurodegenerative diseases such as Alzheimer disease, and antidiabetic activities. Most
importantly curcumin possesses immense antitumorigenic effect. It prevents tumor
invasion and metastasis in a number of animal models, including models of lung, liver,
stomach, colon, breast, esophageal cancer etc. Invasion and metastasis are considered
as one of the hallmarks in cancer biology. The pertinent recent applications of curcumin as
anti-invasive and antimetastatic agent in in vitro and in vivo and ex vivo studies as well as
associated molecular mechanisms have been discussed in this review. Curcumin has also
demonstrated the ability to improve patient outcomes in clinical trials.
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Cancer is neither a single nor a modern disease. In human, more
than 200 different types of cancer are possible depending upon
the types of tissue and/or cell. The description of cancer was
found in many ancient literatures including Egyptian “Edwin
Smith” and “George Ebers” papyri, written between the 3000 BC2
and 1500 BC (Faguet, 2014). The “Edwin Smith” papyrus refers
to 8 cases of ulcers (tumors) of the breast that were removed
by cauterization with a tool called “the fire drill.” It describes
Abbreviations: ADME, Absorption, distribution, metabolism, excretion; APN,
Aminopeptidase N; BBB, Blood brain barrier; b-FGF, basic fibroblast growth
factor; Cav-1, Caveolin-1; CCL2, Chemokines cytokine motif ligand 2; CD,
Cluster of differentiation; COX-2, Cyclooxygenase-2; EGFR, Epidermal growth
factor receptor; EMT, Epithelial-mesenchymal transition; ER, Estrogen receptor;
ERK1/2, Extracellular signal-regulated kinases 1 and 2; FAK, Focal adhesion kinase;
FGF-2, Fibroblast growth factor-2; GBM, Glioblastoma; GM-CSF, Granulocyte
macrophage-colony stimulating factor; HCC, Human hepatocellular carcinoma;
IC50, Half-maximal inhibitory concentration; LPS, Lipopolysac charide; MCP-1,
Monocyte chemoattractant protein 1; MMP, Matrix metalloproteinase; mRNA,
messenger ribonucleic acid; NF-κB-Snail, Nuclear factor κB-Snail; NSCLC, Non-
small cell lung carcinoma; OPN, Osteopontin; PCa, Prostate cancer; PKC, Protein
kinase C; Rho A, Ras homolog gene family, member A; ROCK1, Rho-associated,
coiled-coil-containing protein kinase 1; ROS, Reactive oxygen species; RT-PCR,
Reverse transcription polymerase chain reaction; SCLC, Small cell lung carcinoma;
siRNA, small interference RNA; STAT, Signal transducer and activator of tran-
scription; TGF-β1, Transforming growth factor-β; TIMP-1, Tissue inhibitor of
metalloproteinase-1; TNF-α, Tumor necrosis factor-α; VEGF, Vascular endothelial
growth factor; VM, Vasculogenic mimicry.
1Dedicated to Professor (Dr.) Hiriyakkanavar Ila on the Occasion of Her 70th
Birthday.
2http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/the-history-
of-cancer-what-is-cancer (Accessed on August 30, 2014).
the disease as: “there is no treatment” (Faguet, 2014). A scien-
tific look into the fossils of over 700 dinosaurs confirmed the
existence of bone cancer. Osteosarcoma (growths suggestive of
the bone cancer) was also been noticed in the ancient human
mummies in Egypt. The word oncos (in Greek, it means swelling)
was introduced by a Greek physician Galen (130–200AD) to
define tumors. Successively the term oncology was developed. The
ancient Greek physician Hippocrates (460–370 BC), also known
as the “Father of Medicine,” first differentiated the benign and
malignant tumors by introducing the terms carcinos and carci-
noma to describe non-ulcer forming (benign) and ulcer-forming
(malignant) tumors. The word carcinoma in Greek stands for
crab. Most probably, the disease was symbolized with crab because
of its finger-like tendency to spread throughout the body. Celsus,
an ancient Roman physician (28 BC-50 AD) translated the Greek
word carcinoma into cancer (means crab in Latin). Since then,
several hundred of years no notable progress on understanding
and treatment of cancer was made until 1775 when Percivall
Pott (a British physician) noticed that a number of young boys
employed as chimney sweeps developed cancer of the scrotum
in later life. He suggested the presence of something in the soot
which caused cancer. Therefore, the concept of carcinogen (can-
cer causing agent) was developed (Rothschild et al., 1998, 1999,
2003; Faguet, 2014). With the progress of research and conse-
quently with better understanding the meaning of carcinoma
has been modified and presently it denotes the cancer arising
in epithelial cells that cover external and internal body surfaces;
approximately 90% of all human cancers are of this type. Also
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many other commonly used terms have been developed e.g., sar-
coma (cancer arising in mesenchyme-derived tissue supporting
tissue) which includes cancers of bone, cartilage, fat, connec-
tive tissues and muscle; lymphoma cancer arising in the lymph
nodes and tissues of the immune system, leukemia (cancer of
the immature blood cells that grow in the bone marrow and
tend to accumulate in large numbers in the bloodstream), ade-
noma (cancer of glandular epithelium, in Latin adeno means
gland) etc.
Cancer is the leading cause of death in developed countries and
the second leading cause of death (after cardiovascular and related
diseases) in developing countries3 and accounted for 8.2 million
deaths in 2012 among which 70% occur in low- and middle-
income countries. According to the World Health Organization
the annual cancer cases will rise from 14 million in 2012–2022
within the next two decades4,5. Cancer can spread in the body fol-
lowing two mechanisms: invasion and metastasis. According to
National Cancer Institute, invasion denotes “the direct migration
and penetration by cancer cells into neighboring tissues” whereas
metastasis stands for “the ability of cancer cells to penetrate into
lymphatic and blood vessels, circulate through the bloodstream,
and then invade normal tissues elsewhere in the body”6. To have
a clear understanding, these two mechanisms can be compared
with the ways fire can spread in a locality. When fire spread from
one house to its adjacent house the process can be compared with
invasion where cancer tissue/cells invade from one tumor to its
adjacent body organ and new tumor is formed in that organ. The
spark of fire can also spread from one burning house to a remote
house by air (carrier). This can be compared with the migration
of cancer tissue/cells carrying out by blood or lymph to another
part of the body (for example from lung to liver) and new tumor
is formed in that organ. Invasion and metastasis are considered
as one of the hallmarks in cancer biology. Although cancer is
treated by surgery, radiotherapy, immunotherapy or gene ther-
apy, separately or in combination, still chemotherapy plays crucial
role for the treatment of cancer; particularly to inhibit inva-
sion and metastasis. Therefore, there is a continuous need to
search new anticancer agents to prevent invasion and metasta-
sis and subsequently to reduce cancer-related mortality. Current
research in this field directs to identify potent anti-invasive and
antimetastatic novel chemotherapeutics. A qualitative estimate
states that about 25% drugs are still directly derived from the
Mother Nature and 74-80% of all cancer drugs have their ori-
gins in natural products i.e., these drugs are made by natural
product modification. Of the 1355 new entities introduced as
therapeutics between 1981 and 2010, 71% were natural products
or natural product derived compounds (Hasima and Aggarwal,
2012; Newman and Cragg, 2012).
3http://www.cancer.gov/researchandfunding/priorities/global-research-
activities (Accessed on September 04, 2014).
4http://www.who.int/mediacentre/factsheets/fs297/en (Accessed on Septe-
mber 04, 2014).
5http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed on Septem-
ber 04, 2014).
6http://www.cancer.gov/cancertopics/understandingcancer/cancer/UNDER
CAN.PDF (Accessed on August 30, 2014).
Curcumin (diferuloylmethane), the major constituent of cur-
cuminoids, is present in turmeric which is the dried powered
rhizomes (underground stems) of Curcuma longa Linn of the
Zingiberaceae family. The medicinal use of turmeric (haridra)
was indicated in Sushruta Samhita, one of the three fundamental
texts of Ayurveda (Indian traditional medicine) in the 6th century
BC. Its medicinal uses were also found in Charaka Samhita (300–
500 BC). As Indian traditional medicine (Ayurveda) turmeric
has been using to treat a broad range of common disorders
for over 6000 years (Padhye et al., 2010). In India, turmeric
is used as a cooking spice to induce nice yellow-orange color
and flavor in curries, pickles and chutneys. It is used worldwide
as a color inducing agent as well as preservative in American
mustard, mayonnaise, butter and margarine and has been desig-
nated as international food additive E100 (Epstein et al., 2010).
Turmeric is in the GRAS (Generally Recognized As Safe) list
of the US Food and Drug Administration having GRN num-
ber 4607. This royal spice was introduced to the western world
in the 13th century by Marco Polo, one of the early European
explorers to the Indian subcontinent (Aggarwal et al., 2007;
Basnet and Skalko-Basnet, 2011). Since then India is the high-
est turmeric producing country in the world (Ploto, 2003;
Basnet and Skalko-Basnet, 20118). Turmeric has at least 76 syn-
onyms listed in the 1999 World Health Organization (WHO)
monograph (World Health Organization, 1999). A few popular
names are Haridra (Sanskrit), Halood (Bengali), Haldi (Hindi),
Kurkum uqdah safra (Arabic), Ukon (Japanese), Chiang Huang
(Chinese), Ulgeum (Korean), Kurkuma (German), Safran des
Indes (French), kurkumy (Russian), Indian saffron etc. Besides
its culinary appeal turmeric has a glorious history of uses as
a therapeutic and preventive agent against a wide array of dis-
orders and diseases, either by itself or in combination with
other agents. As an ancient household remedy a hot poultice
of turmeric powder and slaked lime (chun-halood in Bengali) is
applied locally to relieve muscular pain and inflammation caused
by sprain and injury. In some parts of India, a drink made from
fresh turmeric, ginger roots and honey in a glass of hot milk
are given to women twice daily after childbirth. A poultice of
fresh turmeric paste is also applied to the perineum as wound
healing for lacerations in the birth canal (Hatcher et al., 2008).
Its traditional uses as strong therapeutic or preventive agents
against several human diseases include, but are not limited to,
diabetes, fibrosis, asthma, rheumatism, allergies, inflammation,
intestinal worms, atherosclerosis, diarrhea, dyspepsia, intermit-
tent fevers, biliousness, cough, sinusitis, constipation, jaundice,
urinary discharges, flatulence, leukoderma, amenorrhea, acne,
colic inflammation, respiratory ailments, lupus nephritis, irri-
table bowel syndrome, menstrual difficulties, anorexia, coryza,
hematuria, hemorrhage, neurodegenerative such as Alzheimer’s
disease as well as cancer (Ammon and Wahl, 1991; Ploto, 2003;
Chattopadhyay et al., 2004; Salvioli et al., 2007; Hatcher et al.,
2008; Ringman et al., 2012; Gupta et al., 2013b). The presence
7http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?filter=turmeric
&sortColumn=&rpt=grasListing (Access date: September 04, 2014).
8Spices Board of India. Ministry of Commerce and Industry. Available online:
http://www.indianspices.com (Access date: September 04, 2014).
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of turmeric is essential in most of the religious ceremonies in
Hinduism. Besides the ancient literature, the first scientific report
related to the medicinal uses of Curcuma was published in 1748
(Loeber and Buechner, 1748; National Cancer Institute, 1996).
After 67 years a review detailing the biological and medicinal
properties of turmeric (curcumin) was published (Vogel and
Pelletier, 1815). In 1937, Oppenheimer reported the medicinal
activity of turmeric against biliary diseases (Oppenheimer, 1937).
In 1949, Schraufstatter and Bernt reported (Schraufstatter and
Bernt, 1949) the antibacterial activity of curcumin and its phar-
macological activity to cure eye disease was reported (Chaudhri,
1950) in the following year. Jiang and co-workers evaluated the
anticancer activity of four natural products viz. camptothecin,
harringtonin, cantharidin, and curcumin on human tumor biop-
sies in an in vitro soft agar clonogenic assay system and reported
their findings in 1983 (Jiang et al., 1983). They reported cur-
cumin as “relatively ineffective” antitumor agent than camp-
tothecin and harringtonin. Probably this was the first evaluation
of curcumin against cancer. Kuttan and colleagues published
the anticancer activity of curcumin in 1985 (Kuttan et al.,
1985).
The acceptance of traditional medicine is considered as an
alternative form of modern health care system. Over the past
quarter century there has been growing interest in a possible role
of curcumin on various diseases. The research topic “curcumin”
in any chemistry/health related search engine hits a huge number
of results, including research articles, reviews, communications,
patents, books, editorials etc. Comparative results obtained up
to December 31, 2013 from the two major chemistry and health
related databases viz. SciFinder Scholar and PubMed Central are
presented in Figure 1.
The presence of about 235 compounds have been identified
in turmeric of which 109 sesquiterpenes, 68 monoterpenes,
22 diarylheptanoids and diarylpentanoids, 8 phenylpropene,
and other phenolic compounds, 5 diterpenes, 4 sterols, 3
triterpenoids, 2 alkaloids, and 14 other compounds. Among
the diarylheptanoids 3 are curcuminoids, the major phar-
macologically active ingredients of turmeric. Curcumin, the
major curcuminoid which constitutes 3–5% of turmeric has
been consumed for medicinal purposes for thousands of years
(Goel et al., 2008; Gupta et al., 2013b). Two other cur-
cuminoids are demethoxycurcumin and bis-demethoxycurcumin
(Figure 2). Commercial curcumin is a mixture of three cur-
cuminoids: curcumin (71.5%), demethoxycurcumin (19.4%) and
bis-demethoxycurcumin (9.1%) (Gupta et al., 2013b).
The isolation of curcumin, the principal constituent of
turmeric responsible for its vibrant yellow-orange color, first
reported in 1815 (Vogel and Pelletier, 1815) from the plant
Curcuma longa as “yellow coloring-matter” and named as cur-
cumin. Later, it was found to be a mixture of resin and turmeric
oil (Gupta et al., 2012). Curcumin was isolated in 1842 but the
chemical formula was not reported (Vogel, 1842; Gupta et al.,
2012). The chemical structure of curcumin as diferuloylmethane
was identified by Milobedzka et al. (1910) and the first syn-
thesis of curcumin was reported from the same laboratory in
1913 (Milobedzka et al., 1910; Lampe and Milobedzka, 1913;
Gupta et al., 2012). In 1953, Srinivasan reported the chromato-
graphic resolution and quantification of curcumin from curcum-
inoids (Srinivasan, 1953). The chemical structure of curcumin
was confirmed in 1973 (Roughley and Whiting, 1973) and a few
years ago in 2007, its solution structure (Payton et al., 2007) was
reported (Figure 3).
FIGURE 1 | Comparative literature on research with Curcumin.
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FIGURE 2 | Structure of Curcuminoids: The active principle in turmeric.
Since the publication of the preliminary investigations on the
anticancer activity of curcumin as a promising anticancer agent
in the mid-eighties (Jiang et al., 1983; Kuttan et al., 1985), sci-
entists from all over the world have been paying their attention
to this novel nutraceutical. It is now well known that cancer is
neither a single disease nor a comparatively new disease. It has
already been mentioned that invasion and metastasis are two
major problems for the treatment of cancer. Curcumin has suc-
cessfully demonstrated its potential to act as a potent anti-invasive
as well as anti-metastatic agent in vitro, ex vivo and in vivo in
numerous occasions. It can inhibit cancer cell migration and inva-
sion by manipulating several signaling pathways as described in
the sequel.
LUNG CANCER
The overall incidence (13.0%) and cancer-related mortality
(19.4%) in lung cancer were highest worldwide among all can-
cers in 20124,5. About 85-90% lung cancers are non-small cell
lung carcinoma (NSCLC) and 5-year prevalence is only 5.8%
(Vogelstein and Kinzler, 2004). The protein Rac1 (one of the
most important small Rho GTPases family proteins) is exten-
sively associated in cytoskeleton rearrangements and cancer cell
migration, invasion and metastasis. Curcumin at 10μM demon-
strated significant inhibitory effect on epidermal growth factor
or transforming growth factor β1-induced 801D lung cancer cells
migration and invasion. The inhibition of the metastasis ability
(at least partly) detected in curcumin-treated cells was due to
the inhibition of Rac1/PAK1 signaling pathway and the decreased
MMP-2 and MMP-9 expression (Chen et al., 2014). Not only in
NSCLC but also in the small cell lung carcinoma (SCLC) cell lines,
NCI-H446 and NCI-1688, curcumin at 15μM plays notable role
to prevent migration, invasion as well as angiogenesis via Janus
Kinase-STAT3 signaling pathway. It can inhibit STAT3 phospho-
rylation to suppress of an array of STAT3 downstream targets that
are responsible for colony formation, cell migration and inva-
sion. It also suppresses the expression of proliferative proteins
(Survivin, Bcl-XL, and Cyclin B1), and invasive proteins (VEGF,
MMP-2, MMP-7, and ICAM-1). Knockdown of STAT3 expres-
sion by siRNA was able to induce anti-invasive effects in vitro.
Curcumin causes G2/M Phase cell cycle arrest in NCI-H446 cells
in a time-dependent manner (Yang et al., 2012).
Plectin, a high molecular weight (≈500KDa) linker protein
that organizes the cytoskeleton, can play an important role in the
migration and invasion of human NSCLC A549 cells. The down
regulation of plectin gene PLEC1 by siRNA promotes the migra-
tion and invasion of the A549 lung cancer cells. The plectin siRNA
has been reported (Ha et al., 2011) to mitigate by curcumin.
Besides the prevention of plectin siRNA, curcumin demonstrated
its ability to inhibit the matrix metalloproteinase (MMP)-2 and
9 as well as VEGF in human lung cancer A549 cells in vitro.
It is well known that matrix metalloproteinases (MMPs) play a
crucial role in the invasion, metastasis and angiogenesis of can-
cer cells. The down regulation of MMP-2 and -9 occurs through
MEKK and ERK signaling pathways in A549 lung cancer cells
(Lin et al., 2009). On the other hand, curcumin inhibits the inva-
sion and metastasis of human lung adenocarcinoma (CL1-5) cells
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FIGURE 3 | Milestones in Curcumin research.
through activation of the tumor suppressor DnaJ-like heat shock
protein 40 (HLJ1) via activation of the JNK/JunD pathway and by
modulating E-cadherin expression (Chen et al., 2008).
LIVER CANCER
Liver cancer has been rated as the second leading cause of
cancer related deaths (9.1%) worldwide in 2012 with 5-year
prevalence of 1.9% 4,5. In general, hepatocellular carcinoma
is resistant to standard chemotherapy. Surgery or liver trans-
plantation at the early stage may provide longer survival to
the patients. However, about 80% of liver cancer patients with
advanced stage are not amenable to liver transplantation or
surgery and this is the main reason of poor prognosis in liver
cancer (Thomas and Abbruzzese, 2005). Vasculogenic mimicry
(VM) is considered as one of the major factors in cancer inva-
sion and it denotes the process in which the cancer cells mimic
endothelial cells by forming blood channels. The potential of
Curcumin on vasculogenic mimicry of human liver adenocar-
cinoma cells (SK-Hep-1) has been studied in vitro. Curcumin
inhibited vasculogenic mimicry, decreased cell migration and
MMP-9 (matrix metalloproteinase-9) production of the can-
cer cells. Curcumin exhibited the anti-VM efficacy by down-
regulating the Akt (or PKB) and STAT3 signaling pathways
(Chiablaem et al., 2014).
It has been stated earlier that the invasion of cancer cells is con-
sidered as an important and distinctive step toward metastasis.
The blockage of this physiological incident by medicines or sup-
plements/nutraceuticals prolongs the life span of an affected host.
A possible involvement of the antioxidant property of Curcumin
with its anti-invasive ability was investigated (Kozuki et al., 2001).
The efficacy of Curcumin on the proliferation and invasion of
the rat ascites hepatoma AH109A cells was evaluated in vitro
and ex vivo. To satisfy this goal, a co-culture system of the hep-
atoma cells with mesothelial cells derived from rat mesentery was
subjected for invasion study. Curcumin reduced the hepatoma
slipping motility in a concentration-dependent manner up to
5μM and afterward maintained the effect up to 20μM with a
minimum impact on cell proliferation. Interestingly, the sera iso-
lated from rats, those consumed Curcumin orally, also inhibited
the AH109A cellular invasion when added to the culture medium.
Curcumin and curcumin-containing rat sera inhibited the ROS-
potentiated invasive capacity by concurrently treating AH109A
cells with hypoxanthine, xanthine oxidase and either of Curcumin
samples.
High invasive and lymphatic metastasis potential, both in vitro
and in vivo, have been observed inmouse hepatoma cellular carci-
noma Hca-F cells. Curcumin successfully down related Caveolin-
1 (Cav-1, an important structural component in tumormetastasis
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which can potentiate the invasive ability by up-regulating CD-
147 glycosylation level), and inhibited the phosphorylation of
EGFR and the corresponding downstream targets such as MMP-
2 and -9 as well as the phosphoinositilde 3-kinase (PI3K)/protein
kinase B (Akt), p38 mitogen-activated protein kinase (MAPK),
and p44/42MAPK (Wang et al., 2011). Consequently, high level
of anti-invasion was noted in Hca-F cells. The upregulation
of MMP-9 is much higher in human hepatocellular carcinoma
(HCC) SK-Hep-1 cells than HCC Huh-7 cells. Accordingly, SK-
Hep-1 tumor is more invasive than the tumor develops from
Huh-7 cells. Curcumin at 10μM, inhibited the cellular migration
and invasion, 17.4 and 70.6% respectively, in SK-Hep-1 cell lines
by inhibition of MMP-9 secretion (Lin et al., 1998).
A serious concern regarding pharmacological application
of Curcumin is its poor pharmacokinetics (PK) profile. The
bioavailability of Curcumin is low because of poor absorption,
rapid elimination and/or low target organ concentration. This is
due to the reason that Curcumin is conjugated when it is absorbed
through the intestine, consequently free curcumin is present in
extremely low level at the target organ. Moreover, in biological
system it is rapidly converted to its metabolites. Nevertheless,
Curcumin is non-toxic with a dose of 8g/day is well tolerable and
12g/day may cause minor adverse effects like diarrhea, headache,
yellowish stools, and rashes etc. (Anand et al., 2007). Because of
its low bioavailability and half-life, a small portion of the orally
administered Curcumin can reach at the site of action. Therefore,
Curcuminmetabolites have been assumed to be responsible for its
bioactivity. Curcumin glucuronide (Figure 4) was reported as the
major metabolite present in the plasma after oral administration
of Curcumin in rats (Shoji et al., 2014).
Recently an interesting study has been reported to compare
the activity of Curcumin and its major metabolite Curcumin glu-
curonide (synthetic) on gene expression in HepG2 human liver
cancer cell lines in vitro. The RT-PCR (Reverse transcription poly-
merase chain reaction) was used to detect the RNA expression
levels. The effect of Curcumin and Curcumin glucuronide on
mRNA expression of ACOX1, GSTT1, CAT, and AREG genes was
studied. IL-8 expression was also evaluated by real time RT-PCR,
because Curcumin inhibits IL-8 production. The results showed
that the expression of all the tested genes (ACOX1, GSTT1,
CAT, AREG, and IL-8) was significantly decreased by Curcumin
FIGURE 4 | Curcumin glucuronide: The major metabolite of Curcumin.
treatment, whereas the effect of Curcumin glucuronide was found
to be very low. Curcumin glucuronide down-regulated the expres-
sion of GSTT1 to some extent only. In brief, the in vitro cell
culture study suggested that Curcumin per se was highly active,
rather than its major metabolite Curcumin glucuronide (Shoji
et al., 2014).
COLORECTAL (COLON) CANCER
Colorectal cancer is the fourth leading cause of cancer-related
mortality worldwide in 2012 with a 5-years prevalent of 10.9% 4,5.
Cortactin (cortical actin binding protein or CTTN, a monomeric
protein located in the cytoplasm of cells), encoded by the
CTTN/EMS1 gene, is a v-Src substrate localized with cortical actin
at the plasma membrane and is up-regulated in several types of
cancer (Wu et al., 1991). The phosphorylated form of cortactin
(pTyr421) plays major role in cancer cell migration and invasion.
It was shown that pTyr421-cortactin was up-regulated in colon
cancer. Curcumin interacted with PTPN1 tyrosine phosphatases
to rise its efficacy leading to dephosphorylation of pTyr421-
CTTN. Curcumin considerably reduced the pTyr421-CTTN in
HCT116 cells and SW480 (adenocarcinoma of the colon) cells,
but was ineffective in HT-29 (human colorectal adenocarcinoma)
cells. Altogether, Curcumin modulated the activity of PTPN1
phosphatase to reduce cortactin phosphorylation and interaction
with CTNND1, and finally to reduce colon cancer cell migra-
tion (Radhakrishnan et al., 2014). Curcumin activated MAPKs
including Erk1/2 and JNK and inhibited phosphatases 2A (PP2A)
and 5 (PP5). Up-regulation of MAPK cascade induce ROS which
ultimately led to p53-independent apoptosis in cancer cells (Han
et al., 2012). Curcumin inhibited cell viability in human colorectal
cancer cell lines, SW480, HT-29, and HCT116 with IC50 val-
ues ranging between 10.26μM and 13.31μM (Cen et al., 2009).
Curcumin at 10μM, repressed the invasive ability (22.8%) of
murine colon 26-L5 carcinoma cells (Siripong et al., 2002).
BREAST CANCER
The incidence of breast cancer (both genders) was second high-
est among all cancers (11.9%) and it rated as the leading cause
of mortality due to cancer among women worldwide (fifth for
both sexes) in 2012 4,5. Curcumin could successfully inhibit the
proliferation of human breast cancer MDA-MB-435 cells in a
concentration- and time-dependent manner by accumulating the
cells in the G1 phase of the cell cycle. The overexpression of
EZH2 in human breast cancer MDA-MB-435 cells caused poor
prognosis in this type of cancer. The underlying molecular mech-
anism of Curcumin treatment was explained by the activation
of the MAPK signaling pathway. Three major members of the
MAPK family, the p38 kinase, JNK and ERK were stimulated
to down-regulate the enhancer of zeste homolog 2 (EZH2) gene
overexpression leading to proliferation of the cancer cells (Xu
et al., 2013). Activated cancer-associated fibroblasts (CAFs) or
myofibroblasts facilitate the growth of tumor as well as develop
drug-resistance in human breast cancer. Hence effective therapeu-
tic regimen should be able to inhibit the paracrine effects of these
supportive cells. Treatment with Curcumin on patient-derived
primary breast CAF cells overexpressed p16INK4A and other
tumor suppressor proteins while inactivated the JAK2/STAT3
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pathway. This repressed the alpha-smooth muscle actin (α-
SMA) and consequently the cell migration/invasion was reduced
(Hendrayani et al., 2013).
Circulating tumor cells (CTC) are present into the vasculature
from a primary tumor and flow in the bloodstream. Therefore,
CTCs can be considered as seeds for subsequent metastasis in dis-
tant organs, initiating a mechanism that is responsible for the vast
majority of cancer-related deaths (Gupta andMassagué, 2006). As
stated earlier, invasion and metastasis are two serious problems
for the prevention/treatment of cancer. The properties of circulat-
ing tumor cells (CTC) and cancer stem-like cells (CSC) are related
with distant metastasis, but the mechanisms through which CSCs
promote metastasis are not clear. It was reported that breast can-
cer cell lines with more stem-like properties display higher levels
of microtentacles (McTN), a type of tubulin-based protrusion of
the plasma cell membrane that forms on detached or suspended
cells and aid in cell reattachment. Curcumin promptly quenched
McTN in breast CSC, preventing reattachment from suspension.
Overall, a model in which breast CSCs with cytoskeletal alter-
ations that promote McTNs can mediate attachment and metas-
tasis but might be targeted by Curcumin as an anti-metastatic
strategy (Charpentier et al., 2014). Chronic inflammation is a
key risk factor for the growth and metastatic development of
cancer. Curcumin inhibited the expression of the proinflamma-
tory cytokines CXCL-1 and -2 to reduce breast and prostate
cancer metastases. From the microarray miRNA expression anal-
ysis it was found that Curcumin modulated the expression of
a series of miRNAs, including up-regulation of miR181b, in
metastatic breast cancer MDA-MB-231 cells where miR181b
down-regulated the proinflammatory cytokines CXCL-1 and -2
through a direct binding to their 3′-UTR. Curcumin-induced up-
regulation of miR181b in metastatic breast cancer cells inhibited
metastasis formation in vivo in immune-deficient mice (Kronski
et al., 2014). Another study in this field suggested that metastatic
development in human mammary epithelial carcinoma MCF-7
cells was inhibited by Curcumin via the suppression of urokinase-
type plasminogen activator by NF-κB signaling pathways (Zong
et al., 2012). As stated before, MMP-9 is a major factor in can-
cer cell invasion. An invasion-related study in MCF-7 human
breast cancer cells (Kim et al., 2012a) supported that Curcumin
suppressed the TPA-induced MMP-9 expression and subsequent
cell invasion. The molecular mechanism involved Curcumin-
induced inhibition of PKCα-dependent MMP-expression, down-
regulation of NF-κB and reduction of AP-1 activation i.e.,
repression of the PKCα, MAPK and NF-κB/AP-1 pathway in
MCF-7 cells.
It has been found that breast cancer is often associated with
obesity. Most probably the relation between these two factors is
mediated by adipokines. Visfatin [Nicotinamide phosphoribo-
syltransferase (NAmPRTase or Nampt) also known as pre-B-cell
colony-enhancing factor 1 (PBEF1)] is an adipokine, that is local-
ized to the bloodstream and has various functions. The protein
visfatin has recently been shown to be related to the development
and progression of breast cancer. Consequently, suppression of
the gene visfatin might be a novel strategy to fight against breast
cancer. The influence of Curcumin on visfatin gene suppression
was investigated (Kim et al., 2012b). It was found that the mRNA
and protein levels of visfatinwere down-regulated by Curcumin in
human breast cancer MDA-MB-231, MDA-MB-468, and MCF-7
cell lines. In addition, the activity of constitutive nuclear fac-
tor (NF)-κB was reduced. Taken together, visfatin could enhance
the invasion of breast cancer cells which was down-regulated
by Curcumin. Furthermore, visfatin knockdown by siRNA led
to the reduction of cancer cell invasion. Curcumin treatment
could impose anti-migratory activity in human breast cancer
MDA-MB-231 cells (Chiu and Su, 2009). It inhibited prolifer-
ation and migration by increasing the Bax to Bcl-2 ratio and
decreasing NF-κBp65 expression. Integrin (α6β4) is a laminin
adhesion receptor with an established role in the invasion and
migration of cancer cells. Curcumin successfully decreased the
integrin (α6β4)-dependent breast cancer cell motility and inva-
sion in a dose-dependent manner without affecting apoptosis in
MDA-MB-435/β4 (β4-integrin transfectants) and MDA-MB-231
breast cancer cell lines (Kim et al., 2008).
Maspin (mammary serine protease inhibitor) can suppress
tumor growth and metastasis in vivo and tumor cell motility
and invasion in vitro in breast cancer. The maspin expression
in Curcumin-treated MCF-7 (wild type p53) at transcription
and translation levels was analyzed by RT-PCR, immunofluores-
cence, and Western blotting. The results showed a correlation of
maspin expression with p53 and Bcl-2 levels. Curcumin inhib-
ited cell proliferation by inducing apoptosis and up-regulation
of maspin gene expression was observed in MCF-7 cells. These
findings were further correlated with the up-regulation of p53
protein and down-regulation of Bcl-2, suggesting maspin medi-
ated apoptosis in MCF-7 cancer cells (Prasad et al., 2010). These
findings were further correlated with the up-regulation of p53
protein and down-regulation of Bcl-2, suggesting maspin medi-
ated apoptosis in MCF-7 cancer cells (Prasad et al., 2010). The
chemopreventive activity of Curcumin in transformed breast cells
was investigated (Kim et al., 2001). Curcumin inhibited H-ras-
induced invasive phenotype in MCF10A human breast epithelial
cells (H-ras MCF10A); repressed MMP-2 and exerted cytotoxic
effect on H-ras MCF10A cells in concentration-dependent man-
ner. The apoptotic cell death involved significant down-regulation
of Bcl-2 and up-regulation of Bax. Curcumin treatment resulted
in the generation of ROS in H-ras MCF10A cells. In brief, the
results supported that curcumin inhibited invasion and induced
apoptosis in the transformed breast cancer H-ras MCF10A cells.
Plectin can play a pivotal role in the migration and invasion of
human MDA-MB-231 breast cancer cells. The down regulation
of plectin gene PLEC1 by siRNA promotes the migration and
invasion of the MDA-MB-231 cancer cells. The plectin siRNA has
been reported (Ha et al., 2011) to alleviate by curcumin.
Epithelial-mesenchymal transition (EMT), a fundamental
procedure of embryogenesis, is a process by which epithelial
cells gain migratory and invasive abilities by down regulation
of the proteins such as E-cadherin and γ-catenin (subsequent
loss of cell polarity and cell to cell adhesion) and cells may
acquire mesenchymal markers such as MMP-2, and -9, N-
cadherin, fibronectin, vimentin to obtain enhanced ability for
cell migration and invasion. After migrating to a suitable site the
tumor cells up regulate E-cadherin and other epithelial mark-
ers through a process known as MET (mesenchymal-epithelial
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transition). Curcumin showed its ability to inhibit lipopolysac-
charide (LPS) prompted EMT and corresponding morphological
changes in MCF-7 and MDA-MB-231 human breast cancer cell
lines. It down-regulated the LPS-induced markers of EMT such
as vimentin through the downregulation of NF-κB-Snail activity
and up regulated the expression of E-cadherin. The obvious out-
come was inhibition of cell motility and invasiveness in human
breast cancer cell lines in vitro (Huang et al., 2013). A study related
to the effect of curcumin in ER-negative human breast cancer
MDA-MB-231 cells revealed that the anti-invasive effect of cur-
cumin was independent of the presence of estrogen. Curcumin
regulated two common biomolecules MMP-2 (downregulation)
and TIMP-1 (upregulation). It also successfully reduced the tran-
script levels of two major angiogenesis factors VEGF and b-FGF
(Shao et al., 2002).
PROSTATE CANCER
The incidence of prostate cancer was 7.9% of all cancers world-
wide in 2012 with a mortality rate of 3.7% and comparatively
higher (12.1%) five-years prevalent 4,5. Curcumin inhibited the
androgen independent human prostate cancer DU145 and PC3
cell proliferation in a dose-dependent manner and showed its
activity to decrease extensively the cell migration as well as the
detachment of cells seeded on laminin or fibronectin by selec-
tively activating the ERβ, the only isoform present in these
prostate cancers. Hence curcumin might be an effective agent
against human prostate cancer (PCa) progression. Therefore, the
estrogenic effect of curcumin might be protective against PCa
invasion and metastasis (Piccolella et al., 2014). VEGF expression
and secretion are well-correlated with the levels of Osteopontin
(OPN) in PC3 (a human bone-derived androgen-independent
prostate cancer) cells. Phosphorylation of ERK1/2 associated
osteopontin/αvβ3 signaling pathway regulates the expression of
VEGF. Curcumin significantly repressed the phosphorylation of
ERK1/2 and expression of VEGF. It also inhibited the activation
of MMP-9 which could down regulate the secretion of VEGF165b
(an anti-angiogenic factor) and angiostatin (a potent inhibitor of
angiogenesis and an important factor to suppress the growth of
secondary tumors in mice bearing previous tumors) (Gupta et al.,
2013a).
CCL2 (CC motif ligand 2, also known as monocyte chemo
attractant protein-1 or MCP-1) is a small cytokine that belongs
to the Chemokines-chemotactic cytokines family, plays a pivotal
role in the development and progression of PCa bone metastasis
(Lu et al., 2006). Curcumin at 30μM inhibits adhesion, invasion,
and motility of the human PC-3 cells, to some extent through the
down-regulation of CCL2 activity via the inhibition of PKC and
MMP-9 (Herman et al., 2009). It also broadly down regulated the
mRNA expression in PC3 cell lines in vitro.
BRAIN AND NERVOUS SYSTEM CANCER
Brain and nervous system cancer counted 2.3% cancer related
deaths worldwide in 2012 with a poor five-years prevalent
(0.9%)4,5. A major problem for the treatment of brain can-
cer is the presence of blood brain barrier (BBB). Because of
this reason many frontline antiproliferative, anti-invasive, anti-
metastatic, and anti-angiogenic drugs cannot work at all in brain
cancer. Curcumin reduced the proliferation of mouse-rat hybrid
retina ganglion N18 cells through cell cycle (G2/M phase) arrest
and induction of apoptosis. Moreover, it inhibited the invasion
and migration of N18 cells in time- and dose-dependent manner
in vitro. TheWestern blot study revealed that curcumin efficiently
down regulated the protein levels of PKC, FAK, NF-κB p65 and
Rho A leading to the inhibition of ERK1/2, MKK7, COX-2, and
ROCK1 respectively. The inhibition of cell proliferation might
be because of repression of NF-κB p65 and consequently COX-
2 whereas the down regulation of PKC, FAK, and Rho A as well
as their downstream targets ERK1/2, MKK7, and ROCK1 led
to the overall down regulation of MMP-2 and -9, responsible
for N18 cancer cells migration and invasion (Lin et al., 2010).
Curcumin demonstrated anti-proliferative, anti-migratory, and
anti-invasive characteristics against in five human glioblastoma
(GBM) cell lines in vitro. Two human primary glioblastoma cell
lines A-172 and MZ-18 as well as three recurrent GBM (MZ-
54, MZ-256, MZ-304) cell lines were considered for study (Senft
et al., 2010). To evaluate cell proliferation, migration and invasion
of the five GBM cell lines; cell growth assays, monolayer wound
healing assays and modified Boyden chamber trans-well assays
were conducted at different concentrations. Curcumin reduced
the cell growth of the GBM cells in time- and concentration-
dependent manner. The sandwich-ELISA test specified the levels
of the transcription factor phospho-STAT3, a potential target of
curcumin. The effect of curcumin was mediated, at least in part,
by interference with the STAT3 signaling pathway.
NASOPHARYNGEAL CANCER
Nasopharyngeal cancer caused 0.6% mortality due to cancer
worldwide in 2012 with a poor five-years prevalent (0.7%) 4,5. In
pharyngeal carcinoma, mucositis is developed during the admin-
istration of anticancer drugs or radio therapy. It causes delays
in subsequent chemotherapy cycles which may require alter-
ation of dose (reduction) and/or therapeutics. This alteration
very often carries negative influence on overall survival of the
patients. Curcumin is a strong inhibitor of NF-κB activation
and subsequent cytokine release. Preincubation of human pha-
ryngeal carcinoma Detroit 562 cells with 200μM Curcumin for
5–60min resulted in complete suppression of the release of tumor
necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, monocyte
chemoattractant protein 1 (MCP-1), granulocyte macrophage-
colony stimulating factor, and VEGF. Repetitive exposure to cur-
cumin resulted in repetitive suppression of cytokine/chemokine
expression lasting from 4 to 6 h. Most interestingly, the two
wound-healing cytokines (FGF-2 and interferon-γ ) were not
inhibited by curcumin which clearly indicates the selectivity of
curcumin in this process (Luer et al., 2011, 2012). Thus, curcumin
showed strong antibacterial effect against a facultative upper res-
piratory tract pathogen by inhibiting bacterial growth, adherence,
invasion, and proinflammatory activation of upper respiratory
tract epithelial cells in vitro.
BONE CANCER
Besides the above, curcumin displayed its anti-invasive and
anti-metastatic potential against human osteosarcoma in vitro.
Osteosarcoma is an aggressive primary malignancy of the bone,
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predominantly affects rapidly growing bones in adolescents and
children, is characterized by locally aggressive growth and early
metastatic potential arising from primitive transformed cells
of mesenchymal origin (and thus a sarcoma)—that exhibits
osteoblastic differentiation and produces malignant osteoid gen-
erating defective immature bone or osteoid (Luetke et al., 2014).
It predominantly affects children and adolescents and shows an
aggressive tendency for growth and metastasis, with as many as
20% of patients reported to have developed pulmonary metas-
tasis at the time of diagnosis. Regardless of extensive uses of
chemotherapy, radiotherapy and surgery, respiratory failures due
to lung metastases are common events and the major cause of
death in these patients. Curcumin inhibited the cell prolifera-
tion in human osteosarcoma U2OS, SaOS-2 and HOS cells in
a concentration-dependent manner and its anti-invasive poten-
tial in human osteosarcoma U2OS cells was studied. Curcumin
displayed its ability to regulate the Wnt/β-catenin signaling
pathway. It considerably reversed β-catenin plasmid mediated
increase in invasive capacity of U2OS cells in a dose-dependent
manner (Leow et al., 2010, 2014). Other than osteosarcoma,
Curcumin showed its anti-invasive and anti-metastatic capabili-
ties in fibrosarcoma (or fibroblastic sarcoma), a different type of
bone cancer, usually found inmales at the age of below 40 tears. In
fibrosarcoma, the malignant mesenchymal tumor originates from
fibrous connective tissue (also periosteum and overlying muscle)
and recognized by the presence of immature proliferating fibrob-
lasts or undifferentiated anaplastic spindle cells in a storiform
pattern. If all grades are included, primary fibrosarcoma of the
bone has a worse prognosis than osteosarcoma. It is well known
that the net balance of MMPs and tissue inhibitor of metallopro-
teinases (TIMPs) system plays a key role in tumor cell invasion.
The effect of curcumin on the molecular mechanisms of anti-
invasive and antimigratory activity of transforming growth factor
(TGF)-β1 in HT1080 human fibrosarcoma cells was investigated.
Curcumin successfully down regulated theMMP-2, -9 and TIMP-
1, -2 to maintain the net balance of MMPs/TIMPs to inhibit, at
least in part, cancer cell invasion andmigration (Kwak et al., 2006)
in HT1080 human fibrosarcoma cancer cells.
CONCLUSION
Curcumin is a cheap, non-toxic, and easily available natural
polyphenol with excellent medicinal and commercial demands.
Many costly products can be derived very easily from cur-
cumin. For example, Curcumin can easily be converted to vanillin
through a single-step conversion (Bandyopadhyay and Banik,
2012). A huge number of preclinical and early-phase clinical
studies undoubtedly confirmed this nutraceutical as safe with
vast potential of becoming an effective anti-invasive and anti-
metastatic chemotherapeutic, possibly in combination with other
drugs and/or appropriate structural modification for the treat-
ment of cancer. The only concern about this compound is its poor
ADME profile. The bioavailability of curcumin is low because
of poor absorption, rapid elimination and/or low target organ
concentration. On the other hand, curcumin exerted multiple
anticancer properties in vitro, ex vivo and in vivo as well as in clin-
ical trials by regulating a variety of biological pathways involved
in tumor invasion, metastasis and angiogenesis. Based on its huge
therapeutic aspects several active investigations are going on to
overcome the ADME-related drawbacks by introducing new and
novel formulation and route of administration to achieve the
highest therapeutic level. It is highly expected that Curcumin, the
golden spice of India, with novel formulation/route of adminis-
tration will metastasize from curry to capsule for the treatment of
cancer invasion and metastasis.
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